Data / Federal rules / 2026-12059
Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
The Centers for Medicare & Medicaid Services published this proposed rule in the Federal Register on June 16, 2026. Comments closed on August 17, 2026.
SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.
What the agency says
This proposed rule would codify the Medicare Drug Price Negotiation Program ("Negotiation Program") and would establish certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. This proposed rule would also propose a modification to the fixed combination drug policy.
Key facts
- Document number
- 2026-12059
- Type
- Proposed rule
- Action
- Proposed rule
- Agency
- Health and Human Services Department; Centers for Medicare & Medicaid Services
- Published
- June 16, 2026
- Comments due
- August 17, 2026
- Dates
- To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on August 17, 2026.
- Docket
- CMS-4215-P
- Regulation ID (RIN)
- 0938-AV90
- Code of Federal Regulations
- 42 CFR 423; 42 CFR 429
- Topics
- Administrative practice and procedure; Biologics; Health facilities; Medicare; Penalties; Prescription drugs; Privacy; Reporting and recordkeeping requirements
- Pages
- 133
Other documents from the Centers for Medicare & Medicaid Services
Everything from the Centers for Medicare & Medicaid Services · Rules on administrative practice and procedure · Rules on biologics · Rules on health facilities · Published in June 2026
Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.